Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

HUTCHMED (China) stock

13.HK
KYG4672N1198
A2PJ5B

Price

0.32
Today +/-
-0.00
Today %
-1.17 %

HUTCHMED (China) stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the HUTCHMED (China) stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the HUTCHMED (China) stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the HUTCHMED (China) stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze HUTCHMED (China)'s market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

HUTCHMED (China) Stock Price History

DateHUTCHMED (China) Price
3/3/20250.32 undefined
2/28/20250.32 undefined
2/27/20250.34 undefined
2/26/20250.33 undefined
2/25/20250.31 undefined
2/24/20250.31 undefined
2/21/20250.32 undefined
2/20/20250.30 undefined
2/19/20250.29 undefined
2/18/20250.27 undefined
2/17/20250.27 undefined
2/14/20250.27 undefined
2/13/20250.26 undefined
2/12/20250.25 undefined
2/11/20250.26 undefined
2/10/20250.26 undefined
2/7/20250.26 undefined
2/6/20250.28 undefined
2/5/20250.27 undefined
2/4/20250.26 undefined
2/3/20250.26 undefined

HUTCHMED (China) Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into HUTCHMED (China), a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by HUTCHMED (China) from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects HUTCHMED (China)’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of HUTCHMED (China). Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into HUTCHMED (China)’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing HUTCHMED (China)’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on HUTCHMED (China)’s growth potential.

HUTCHMED (China) Revenue, EBIT and net profit per share

DateHUTCHMED (China) RevenueHUTCHMED (China) EBITHUTCHMED (China) Net Income
2030e1.92 B undefined0 undefined0 undefined
2029e1.74 B undefined521.83 M undefined0 undefined
2028e1.55 B undefined383.41 M undefined0 undefined
2027e1.32 B undefined269.5 M undefined229.37 M undefined
2026e957.24 M undefined63.55 M undefined116.81 M undefined
2025e800.03 M undefined-5.76 M undefined111.2 M undefined
2024e690.35 M undefined-73.79 M undefined-27.05 M undefined
2023838 M undefined18.38 M undefined100.78 M undefined
2022426.41 M undefined-407.69 M undefined-360.84 M undefined
2021356.13 M undefined-328.32 M undefined-194.65 M undefined
2020227.98 M undefined-196.67 M undefined-125.73 M undefined
2019204.89 M undefined-146.39 M undefined-106.02 M undefined
2018214.11 M undefined-92.64 M undefined-74.81 M undefined
2017241.2 M undefined-53.42 M undefined-26.74 M undefined
2016216.08 M undefined-46.7 M undefined11.7 M undefined
2015178.2 M undefined-9.77 M undefined-35.01 M undefined
201487.33 M undefined-18.26 M undefined-32.82 M undefined
201346 M undefined-1 M undefined5.9 M undefined
2012195.4 M undefined-1.3 M undefined3.6 M undefined
2011166.9 M undefined5.2 M undefined700,000 undefined
2010134.5 M undefined-3.1 M undefined-6.9 M undefined
2009111 M undefined-5.6 M undefined-8.7 M undefined
200887 M undefined-15.4 M undefined-17.8 M undefined
200765.1 M undefined-9.7 M undefined-17.2 M undefined
200657.5 M undefined-8.2 M undefined-9.6 M undefined
200537.9 M undefined-6.2 M undefined-6.8 M undefined
200417.5 M undefined-5.3 M undefined-6.7 M undefined

HUTCHMED (China) Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
0.010.020.040.060.070.090.110.130.170.20.050.090.180.220.240.210.20.230.360.430.840.690.80.961.321.551.741.92
-30.77117.6554.0514.0433.8527.5920.7223.8817.47-76.4189.13104.6021.3511.57-11.20-4.6711.2756.8319.6696.48-17.5615.9419.6337.5117.7812.5210.32
61.5464.7162.1659.6556.9257.4759.4658.9655.4249.2350.0032.1837.6427.3126.9732.7121.5717.1827.2527.0054.1265.6556.6347.3434.4229.2325.9723.54
81123343750667992962328675965704439971154530000000
-10-6-6-9-17-17-8-6035-32-3511-26-74-106-125-194-360100-27111116229000
--40.00-50.0088.89--52.94-25.00--66.67-740.009.38-131.43-336.36184.6243.2417.9255.2085.57-127.78-127.00-511.114.5097.41---
512.1512.1512.1457.1512.2512.3512.3515.3526.5526.5528.8525.63546.59599.71617.17664.26665.68697.93792.68847.14869.20000000
----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The HUTCHMED (China) Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the HUTCHMED (China) is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
20032004200520062007200820092010201120122013201420152016201720182019202020212022
                                       
00.020.010.070.050.040.040.050.050.060.050.050.030.10.360.30.220.441.010.63
4.85.512.916.621.222.420.130.751.644.313.434.435.2245.0442.2742.9643.2546.9382.4197.99
0.11.21.5000001.51521.611.064.1316.3414.3235.7319.9966.8230.67
2.32.78.79.511.714.717.526.628.725.31.44.49.5612.8211.7912.3116.2119.7735.7656.69
1.40.21.32.12.22.64.65.15.13.93.42.61.431.072.5703.777.0414.1322.33
0.010.030.030.10.090.080.080.110.140.150.070.090.090.170.430.370.320.531.210.84
11.713.32222.925.73230.729.929.533.36.58.99.8511.1715.4817.7927.4832.1953.1584.67
0.80.700.10.10.10.1000111.4113119.76158.51144.24138.3298.94139.5176.4873.78
000000030000000016.19000
2.910.956.40.5510.314.915.600.70.570.470.430.350.28000
2.42.45.96.26.67.17.57.78.28.30.423.333.143.313.193.11000
1.91.84.100.30.30.61.21.61.60.30.36.581.772.281.942.121.6930.9531.11
19.719.232.934.239.14043.952.154.258.8118.6124.9140.09175.06165.74161.58148.1193.38160.59189.56
0.030.050.060.130.130.120.130.160.190.210.190.220.230.340.60.530.470.721.371.03
                                       
00051.251.251.251.351.751.75252.153.156.5360.7166.4566.6666.6972.7786.4586.48
0000.090.090.090.090.090.090.090.090.10.110.210.50.510.510.821.511.5
-20.6-27.4-34.1-41.4-56.2-73-81.7-90.4-88.6-84.5-68.9-66-92.04-80.36-107.1-183-289.73-415.59-610.33-971.48
000.51.83.95.54.85.28.79.412.19.55.02-4.285.43-0.24-3.854.485.57-1.9
00000000000000000000
-20.6-27.4-33.6102.990.375.165.959.564.870.68994.983.36184.27461.73389288.01484.12986.89610.37
3.91.73.98.911.812.817.919.926.428.94.220.424.0935.5424.3725.6323.9631.6141.1871.12
0005.18.77.110.113.710.915.78.47.220.9627.2532.7648.4573.54110.75193.51246.02
48.163.784.822.95.813.79.621.225.314.415.312.9412.3815.9411.412.3913.2650.0736.77
000000000000001.5500000
07.27.47.16.67.68.124.53011.251.526.323.0819.9629.9903.222.7926.910
5272.696.123.13033.349.867.788.581.178.569.281.0695.12104.685.48113.1158.4311.66353.9
0000000.10026.9026.926.7726.83026.7429.8732.937.1623.3
000000.30.81.41.92.72.42.93.4244.454.843.165.062.772.71
0000001.622.127.115.20016.0812.433.912.816.098.7811.5612.66
000000.32.523.52944.82.429.846.2643.268.3734.3839.1246.7721.4938.67
5272.696.123.13033.652.391.2117.5125.980.999127.32138.38112.97119.86152.22205.17333.15392.58
0.030.050.060.130.120.110.120.150.180.20.170.190.210.320.570.510.440.691.321
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of HUTCHMED (China) provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand HUTCHMED (China)'s financial health and stability.

Assets

HUTCHMED (China)'s assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that HUTCHMED (China) must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of HUTCHMED (China) after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into HUTCHMED (China)'s financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-13-7-6-8-15-16-7-5137-41014-22-71-103-115-167-360101
112234444401222346788
000000000000000000000
-2-6-90-1-313-21-611424-33341424411582100114
420262025-3-7-13-18-60-29-7-26-68-126-17-4
0000000001,0001,0001,0001,0001,0000000000
0000011233100233355183
-9-10-13-3-7-1311-1951558-9-9-8-32-80-62-204-268219
-9-3-1-2-7-3-7-8-6-12-2-3-3-4-5-6-8-19-16-36-32
-9-3-27-2-7-3-7-11-5-11-2-158-33-26043119-125-306296-291
00-260000-2000-1112-29-25550127-105-289333-258
000000000000000000000
0700000-100-1813-5-3-4-16-4000-961
00068000200-4020109300-10306690-47-3
20263070-2103374130-592273-8-1296650-8248
2019302-10-12382701-1-13-10-2-1-9-39-25-9
000000000000000000000
113-1065-17-15338816-7-7475035114141-64-29
-19.07-13.11-15.27-5.71-14.9-16.454.41-28.3-0.963.582.534.63-12.71-13.9-13.96-39.21-89.48-81.65-220.98-305.26186.65
000000000000000000000

HUTCHMED (China) stock margins

The HUTCHMED (China) margin analysis displays the gross margin, EBIT margin, as well as the profit margin of HUTCHMED (China). The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for HUTCHMED (China).

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the HUTCHMED (China)'s sales revenue. A higher gross margin percentage indicates that the HUTCHMED (China) retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the HUTCHMED (China)'s earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the HUTCHMED (China)'s total revenue generated. When comparing the revenue margin year over year, investors can gauge the HUTCHMED (China)'s growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the HUTCHMED (China). Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the HUTCHMED (China)'s financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

HUTCHMED (China) Margin History

HUTCHMED (China) Gross marginHUTCHMED (China) Profit marginHUTCHMED (China) EBIT marginHUTCHMED (China) Profit margin
2030e54.12 %0 %0 %
2029e54.12 %29.92 %0 %
2028e54.12 %24.74 %0 %
2027e54.12 %20.48 %17.43 %
2026e54.12 %6.64 %12.2 %
2025e54.12 %-0.72 %13.9 %
2024e54.12 %-10.69 %-3.92 %
202354.12 %2.19 %12.03 %
202227.04 %-95.61 %-84.62 %
202127.49 %-92.19 %-54.66 %
202017.31 %-86.27 %-55.15 %
201921.84 %-71.45 %-51.75 %
201832.77 %-43.27 %-34.94 %
201727.11 %-22.15 %-11.08 %
201627.65 %-21.61 %5.41 %
201537.84 %-5.48 %-19.65 %
201432.61 %-20.91 %-37.58 %
201351.74 %-2.17 %12.83 %
201249.13 %-0.67 %1.84 %
201155.6 %3.12 %0.42 %
201059.41 %-2.3 %-5.13 %
200959.82 %-5.05 %-7.84 %
200858.39 %-17.7 %-20.46 %
200757.6 %-14.9 %-26.42 %
200659.3 %-14.26 %-16.7 %
200561.21 %-16.36 %-17.94 %
200466.29 %-30.29 %-38.29 %

HUTCHMED (China) Stock Sales Revenue, EBIT, Earnings per Share

The HUTCHMED (China) earnings per share therefore indicates how much revenue HUTCHMED (China) has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue HUTCHMED (China) earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates HUTCHMED (China)'s earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of HUTCHMED (China)’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating HUTCHMED (China)'s prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

HUTCHMED (China) Revenue, EBIT and net profit per share

DateHUTCHMED (China) Sales per ShareHUTCHMED (China) EBIT per shareHUTCHMED (China) Earnings per Share
2030e2.21 undefined0 undefined0 undefined
2029e2 undefined0 undefined0 undefined
2028e1.78 undefined0 undefined0 undefined
2027e1.51 undefined0 undefined0.26 undefined
2026e1.1 undefined0 undefined0.13 undefined
2025e0.92 undefined0 undefined0.13 undefined
2024e0.79 undefined0 undefined-0.03 undefined
20230.96 undefined0.02 undefined0.12 undefined
20220.5 undefined-0.48 undefined-0.43 undefined
20210.45 undefined-0.41 undefined-0.25 undefined
20200.33 undefined-0.28 undefined-0.18 undefined
20190.31 undefined-0.22 undefined-0.16 undefined
20180.32 undefined-0.14 undefined-0.11 undefined
20170.39 undefined-0.09 undefined-0.04 undefined
20160.36 undefined-0.08 undefined0.02 undefined
20150.33 undefined-0.02 undefined-0.06 undefined
20140.17 undefined-0.03 undefined-0.06 undefined
20130.09 undefined-0 undefined0.01 undefined
20120.37 undefined-0 undefined0.01 undefined
20110.32 undefined0.01 undefined0 undefined
20100.26 undefined-0.01 undefined-0.01 undefined
20090.22 undefined-0.01 undefined-0.02 undefined
20080.17 undefined-0.03 undefined-0.03 undefined
20070.13 undefined-0.02 undefined-0.03 undefined
20060.13 undefined-0.02 undefined-0.02 undefined
20050.07 undefined-0.01 undefined-0.01 undefined
20040.03 undefined-0.01 undefined-0.01 undefined

HUTCHMED (China) business model

Hutchison China MediTech Ltd is a Hong Kong-based company specializing in the development and marketing of innovative medications. It has become a significant player in the Asian pharmaceutical industry since its listing on the London Stock Exchange in 2006. The company was founded in 2000 by a team of pharmaceutical experts and scientists and has since evolved into an independent pharmaceutical company. It focuses on developing medications for cancer and inflammatory diseases, incorporating both Western and Chinese medicine practices. Hutchison China MediTech operates in three divisions: innovation, marketing, and manufacturing. It has various medications in its development pipeline, including cancer drugs such as fruquintinib and surufatinib, as well as an anti-inflammatory medication called Naronaprid. The company's headquarters are in Hong Kong, with subsidiaries in Shanghai, Beijing, and Suzhou. Hutchison China MediTech collaborates closely with universities and research institutions globally to advance the development of new medications. Overall, the company has established itself as a significant player in the Asian pharmaceutical industry, operating in a crucial market for the development of innovative medications. HUTCHMED (China) is one of the most popular companies on Eulerpool.com.

HUTCHMED (China) SWOT Analysis

Strengths

Hutchison China MediTech (Chi-Med) has several strengths that contribute to its success in the pharmaceutical industry:

  • Strong Research and Development (R&D) Capabilities: Chi-Med focuses on discovering and developing innovative medicines, leveraging its deep R&D expertise.
  • Robust Pipeline: The company has a robust pipeline of drug candidates across multiple therapeutic areas, providing potential future growth opportunities.
  • Specialization in Oncology: Chi-Med's expertise in the field of oncology allows it to address a critical healthcare need and tap into a growing market.
  • Access to China's Healthcare Market: As a China-based company, Chi-Med has a competitive advantage in accessing and serving the rapidly expanding Chinese healthcare market.

Weaknesses

Chi-Med faces some weaknesses that pose challenges to its growth and competitiveness:

  • Dependency on a Small Number of Products: The success of Chi-Med heavily relies on the performance of a limited number of products, leading to concentration risks.
  • Regulatory and Market Risks: The pharmaceutical industry is subject to stringent regulations and market uncertainties, which may impact Chi-Med's ability to obtain necessary approvals and commercialize its products.
  • Relatively Small Scale: Compared to large multinational pharmaceutical companies, Chi-Med's relatively small scale may limit its resources and ability to compete in terms of marketing, distribution, and R&D investments.

Opportunities

Several opportunities exist for Chi-Med to further expand and enhance its market position:

  • Growing Global Oncology Market: The increasing prevalence of cancer globally presents a significant market opportunity for Chi-Med's oncology-focused portfolio.
  • China's Healthcare Reforms: Ongoing healthcare reforms in China, aimed at improving accessibility and affordability, can create a more favorable market environment for Chi-Med's products.
  • Partnerships and Collaborations: Collaborating with strategic partners, such as multinational pharmaceutical companies or academic institutions, can bring additional resources, expertise, and market access to Chi-Med.

Threats

Chi-Med faces certain threats that may impact its business operations and growth prospects:

  • Competition: The pharmaceutical industry is highly competitive, with numerous players vying for market share, which may erode Chi-Med's market position.
  • Intellectual Property Risks: Protecting intellectual property rights is crucial for Chi-Med, as any infringement or challenges to patents may affect its ability to commercialize products and generate revenue.
  • Market Entry Barriers: Various regulatory, legal, and financial barriers in new markets may hinder Chi-Med's expansion efforts and delay market entry.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

HUTCHMED (China) Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

HUTCHMED (China) historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

HUTCHMED (China) shares outstanding

The number of shares was HUTCHMED (China) in 2024 — This indicates how many shares 869.196 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue HUTCHMED (China) earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates HUTCHMED (China)'s earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of HUTCHMED (China)’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating HUTCHMED (China)'s prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for HUTCHMED (China).

HUTCHMED (China) latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2023-0.38 0.19  (149.86 %)2023 Q2
12/31/2021-1.06 -0.26  (75.59 %)2021 Q4
6/30/2021-0.77 -0.14  (81.88 %)2021 Q2
12/31/2020-0.44 -0.11  (75.16 %)2020 Q4
6/30/2020-0.55 -0.07  (87.18 %)2020 Q2
1

Eulerpool ESG Scorecard© for the HUTCHMED (China) stock

Eulerpool World ESG Rating (EESG©)

77/ 100

🌱 Environment

85

👫 Social

86

🏛️ Governance

60

Environment

Scope 1 - Direct Emissions
320
Scope 2 - Indirect emissions from purchased energy
6,640
Scope 3 - Indirect emissions within the value chain
71,812
Total CO₂ emissions
6,960
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees53.189
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

HUTCHMED (China) shareholders

%
Name
Stocks
Change
Date
38.14580 % Hutchison Healthcare Holdings Ltd.332,478,770-95,88012/31/2023
3.53918 % The Carlyle Group30,847,500-10,000,0008/20/2024
2.06144 % HuaAn Fund Management Co., Ltd.17,967,50012,508,5006/30/2024
1.59621 % The Vanguard Group, Inc.13,912,528-56,5001/31/2025
1.46861 % Norges Bank Investment Management (NBIM)12,800,446-1,118,53212/31/2024
1.44080 % GF Fund Management Co., Ltd.12,558,0003,220,0006/30/2024
1.22982 % Fullgoal Fund Management Co., Ltd.10,719,1064,130,1066/30/2024
1.05949 % M&G Investment Management Ltd.9,234,485-176,50011/30/2024
1.03855 % Bosera Asset Management Co., Ltd.9,052,000-28,0006/30/2024
0.98440 % Bank of China Investment Management Co., Ltd.8,580,000-1,065,5006/30/2024
1
2
3
4
5
...
10

HUTCHMED (China) Executives and Management Board

Dr. Weiguo Su

(65)
HUTCHMED (China) Chief Executive Officer, Chief Scientific Officer, Executive Director (since 2017)
Compensation 3.62 M

Mr. Chig Fung Cheng

(56)
HUTCHMED (China) Chief Financial Officer, Executive Director (since 2011)
Compensation 1.62 M

Mr. Paul Carter

(62)
HUTCHMED (China) Senior Independent Non-Executive Director
Compensation 256,000

Mr. Graeme Jack

(73)
HUTCHMED (China) Independent Non-Executive Director
Compensation 250,000

Prof. Shu Kam Mok

(62)
HUTCHMED (China) Independent Non-Executive Director
Compensation 242,000
1
2
3
4

Most common questions regarding HUTCHMED (China)

What values and corporate philosophy does HUTCHMED (China) represent?

Hutchison China MediTech Ltd (Chi-Med) represents a strong corporate philosophy focused on innovation, patient-centricity, and scientific excellence. The company strives to improve healthcare outcomes through its cutting-edge therapies and medicines. Hutchison China MediTech Ltd values transparency, integrity, and collaboration, fostering partnerships with healthcare professionals, patients, and the broader community. With a commitment to research and development, Chi-Med aims to address unmet medical needs and provide effective solutions for patients. By continuously pushing boundaries and leveraging its expertise, Hutchison China MediTech Ltd strives to deliver high-quality healthcare products, contributing to the advancement of the medical industry.

In which countries and regions is HUTCHMED (China) primarily present?

Hutchison China MediTech Ltd, commonly known as Chi-Med, primarily operates in China and the United States. As a multinational biopharmaceutical company, Chi-Med focuses on discovering, developing, and commercializing innovative medicines. With its headquarters in Hong Kong and clinical development operations in mainland China, Chi-Med maintains a significant presence in these regions. Additionally, the company has expanded its reach to the United States, establishing a presence in order to access global markets, collaborate with key stakeholders, and enhance its international footprint. Chi-Med's commitment to growth and collaboration across these countries and regions strengthens its position in the global healthcare market.

What significant milestones has the company HUTCHMED (China) achieved?

Hutchison China MediTech Ltd, also known as Chi-Med, has achieved several significant milestones. One notable achievement is the successful development and commercialization of innovative oncology and immunology drugs. The company has obtained approvals from global regulatory authorities for multiple drugs in various indications. Additionally, Chi-Med has entered into strategic partnerships with renowned international pharmaceutical companies for the co-development and commercialization of certain products. Moreover, the company has expanded its operations globally, establishing subsidiaries and research centers in multiple countries. These achievements demonstrate Hutchison China MediTech Ltd's commitment to advancing healthcare through groundbreaking research and development.

What is the history and background of the company HUTCHMED (China)?

Hutchison China MediTech Ltd (Chi-Med) is a leading biopharmaceutical company based in China. Founded in 2000, the company focuses on researching, developing, and commercializing innovative therapies in oncology and immunology. Chi-Med has a strong track record in discovering and developing novel, targeted therapies, with a particular emphasis on precision medicines. The company has successfully launched multiple drugs in China and is expanding its global presence. Chi-Med's commitment to transforming healthcare has earned it recognition and numerous awards within the industry. With a dedicated team and breakthrough innovations, Hutchison China MediTech Ltd continues to make significant contributions to the field of biopharmaceuticals.

Who are the main competitors of HUTCHMED (China) in the market?

Some of the main competitors of Hutchison China MediTech Ltd in the market include BeiGene Ltd, Simcere Pharmaceutical Group, and Zai Lab Ltd.

In which industries is HUTCHMED (China) primarily active?

Hutchison China MediTech Ltd, also known as Chi-Med, is primarily active in the biopharmaceutical industry.

What is the business model of HUTCHMED (China)?

Hutchison China MediTech Ltd, also known as Chi-Med, operates under a diversified business model in the healthcare sector. The company focuses on research and development of innovative medicines, primarily in oncology and immunology therapeutic areas. Chi-Med's business model encompasses developing both internally discovered and externally sourced products, and commercializing them through strategic partnerships and independent commercialization efforts. With a strong pipeline of potential drug candidates and expertise in precision medicine, Chi-Med aims to bring novel therapies to patients and improve healthcare outcomes. By leveraging its integrated platform, Chi-Med strives to become a leading biopharmaceutical company in China and globally.

What is the P/E ratio of HUTCHMED (China) 2025?

The HUTCHMED (China) P/E ratio is 2.5.

What is the P/S ratio of HUTCHMED (China) 2025?

The HUTCHMED (China) P/S ratio is 0.35.

What is the Quality Investing of HUTCHMED (China)?

The Quality Investing for HUTCHMED (China) is 3/10.

What is the revenue of HUTCHMED (China) 2025?

The expected HUTCHMED (China) revenue is 800.03 M USD.

How high is the profit of HUTCHMED (China) 2025?

The expected HUTCHMED (China) profit is 111.2 M USD.

What is the business model of HUTCHMED (China)

Hutchison China MediTech Limited (Chi-Med) is a pharmaceutical company that focuses on developing, manufacturing, and marketing innovative drugs in China and globally. The company has three main business areas: Innovative oncology products, consumer health, and research and development platforms.

What is the HUTCHMED (China) dividend?

HUTCHMED (China) pays a dividend of 0 USD distributed over payouts per year.

How often does HUTCHMED (China) pay dividends?

The dividend cannot currently be calculated for HUTCHMED (China) or the company does not pay out a dividend.

What is the HUTCHMED (China) ISIN?

The ISIN of HUTCHMED (China) is KYG4672N1198.

What is the HUTCHMED (China) WKN?

The WKN of HUTCHMED (China) is A2PJ5B.

What is the HUTCHMED (China) ticker?

The ticker of HUTCHMED (China) is 13.HK.

How much dividend does HUTCHMED (China) pay?

Over the past 12 months, HUTCHMED (China) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, HUTCHMED (China) is expected to pay a dividend of 0 USD.

What is the dividend yield of HUTCHMED (China)?

The current dividend yield of HUTCHMED (China) is .

When does HUTCHMED (China) pay dividends?

HUTCHMED (China) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of HUTCHMED (China)?

HUTCHMED (China) paid dividends every year for the past 0 years.

What is the dividend of HUTCHMED (China)?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is HUTCHMED (China) located?

HUTCHMED (China) is assigned to the 'Health' sector.

Wann musste ich die Aktien von HUTCHMED (China) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of HUTCHMED (China) from 3/4/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/4/2025.

When did HUTCHMED (China) pay the last dividend?

The last dividend was paid out on 3/4/2025.

What was the dividend of HUTCHMED (China) in the year 2024?

In the year 2024, HUTCHMED (China) distributed 0 USD as dividends.

In which currency does HUTCHMED (China) pay out the dividend?

The dividends of HUTCHMED (China) are distributed in USD.

All fundamentals about HUTCHMED (China)

Our stock analysis for HUTCHMED (China) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of HUTCHMED (China) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.